8-K: Propanc Biopharma Secures $58,000 in Convertible Note Financing with Steep Terms

Propanc Biopharma, Inc. has entered into a Securities Purchase Agreement to issue a convertible promissory note for $58,000, incurring a principal amount of $67,860 and a one-time 15% interest charge, with a maturity date of April 16, 2026.

Summary

• Propanc Biopharma, Inc. (the "Company") secured $58,000 in financing from 1800 DIAGONAL LENDING LLC (the "Holder") through a Convertible Promissory Note.
• The Note has a principal amount of $67,860.00, including an Original Issue Discount (OID) of $9,860.00.
• A one-time interest charge of 15% ($10,179.00) is applied to the principal on the Issue Date.
• The total payback to the Holder is $78,039.00.
• The Note matures on April 16, 2026.
• Payments are structured in five installments: $39,019.50 on December 15, 2025, and four subsequent monthly payments of $9,754.88 (with the last one being $9,754.86) from January 15, 2026, to April 15, 2026.
• The Company can prepay the Note in full at any time without penalty, with a 97% prepayment percentage if done within 180 days of the Issue Date.
• In case of default, the Note bears a Default Interest rate of 22% per annum.
• Upon an Event of Default, the Note becomes immediately due and payable at 150% of the outstanding principal, accrued interest, and default interest.
• The Holder has the right to convert the outstanding amount into common stock at a conversion price of 65% of the lowest trading price during the ten trading days prior to conversion, subject to a 4.99% beneficial ownership limitation.
• The Company will use the net proceeds for general working capital purposes.

Sentiment

Score: 3

Explanation: The financing terms, including a substantial original issue discount, high one-time interest charge, and a deeply discounted conversion price upon default, are highly unfavorable to the company and its existing shareholders. The 150% penalty upon default further exacerbates financial risk. While it provides immediate working capital, the cost and potential for significant dilution suggest a challenging financial position.

Positives

• Secured $58,000 in immediate working capital.
• Company retains the right to prepay the Note in full at any time without penalty.

Negatives

• High effective cost of capital: $58,000 purchase price for a $67,860 principal amount (effectively $9,860 OID) plus a 15% one-time interest charge ($10,179), leading to a total payback of $78,039.00.
• Significant dilution risk for existing shareholders if the Note is converted into common stock, especially at a 35% discount to the lowest trading price during the 10 days prior to conversion.
• High penalty for Events of Default: 150% of the outstanding principal and accrued interest becomes immediately due and payable.
• The Note is unsecured, meaning no collateral is pledged to the Holder.
• High default interest rate of 22% per annum.

Risks

• Dilution Risk: Potential for significant dilution of existing shareholders' equity if the convertible note is converted into common stock, particularly given the 35% discount to the lowest trading price upon conversion.
• Financial Strain/Liquidity Risk: The company faces substantial repayment obligations totaling $78,039.00 by April 2026, with a large initial payment of $39,019.50 due by December 15, 2025, which could strain liquidity.
• Default Risk: Numerous events of default, including failure to make payments, breach of covenants, delisting of common stock, or failure to comply with SEC reporting requirements, could trigger immediate repayment at a 150% penalty.
• Operational Continuity Risk: Cessation of operations or inability to pay debts as they become due (excluding going concern disclosures) are defined as Events of Default.
• Market Risk: The conversion price is tied to the lowest trading price, which could incentivize the Holder to engage in activities that depress the stock price to maximize conversion shares.
• Regulatory Compliance Risk: Failure to maintain common stock listing on a qualified exchange or comply with Exchange Act reporting requirements constitutes an Event of Default.

Future Outlook

The company intends to use the net proceeds from this financing for general working capital purposes. No specific forward-looking statements regarding operational performance or future financial guidance are provided beyond the repayment schedule of this note.

Management Comments

• The Company intends to use the net proceeds therefrom for general working capital purposes.
• The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby.
• The Company acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees... that the Holder shall be entitled... to an injunction or injunctions restraining, preventing or curing any breach... without the necessity of showing economic loss and without any bond or other security being required.

Industry Context

This type of high-cost, dilutive financing (convertible note with significant discount and default penalties) is often utilized by smaller, early-stage, or financially distressed companies that may have limited access to traditional debt or equity markets. It suggests a pressing need for capital that cannot be met through more favorable means, which is common in the biotech or biopharma industry where R&D costs are high and revenue generation can be distant.

Comparison to Industry Standards

• The 35% discount on conversion to the lowest trading price is significantly higher than typical convertible debt terms for financially stable companies, which usually offer discounts in the 10-20% range or even premiums. This indicates a distressed financing scenario.
• The 15% one-time interest charge on the principal, combined with the Original Issue Discount, results in a very high effective interest rate for the $58,000 raised, far exceeding standard corporate borrowing rates.
• The 150% penalty upon default is an aggressive term, reflecting the high risk perceived by the lender.
• The unsecured nature of the note, despite the high cost, suggests the company may not have sufficient unencumbered assets to offer as collateral, or the lender preferred the conversion rights over secured debt.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the convertible nature of the note, especially if converted at a deep discount upon default. The high cost of financing and potential default penalties could negatively impact shareholder value.
• Creditors: The new note is unsecured, meaning it does not have priority over secured creditors. However, the aggressive default terms provide strong remedies for the note holder.
• Management: Increased pressure to manage cash flow effectively to meet repayment obligations and avoid triggering Events of Default, which carry severe penalties.

Next Steps

• Make the first mandatory payment of $39,019.50 by December 15, 2025.
• Make subsequent monthly payments of $9,754.88 (or $9,754.86 for the last) from January 15, 2026, to April 15, 2026.
• Ensure compliance with all covenants to avoid Events of Default, including maintaining stock listing and SEC reporting.
• Manage cash flow to meet repayment obligations by the April 16, 2026, maturity date.

Key Dates

Keywords

Convertible Promissory Note, Securities Purchase Agreement, Debt Financing, Working Capital, SEC Filing, 8-K, Dilution, Default Risk, Unsecured Debt, Corporate Finance, Capital Raise, PROPANC BIOPHARMA, 1800 DIAGONAL LENDING